NSE:APLLTD

10 stories mentioning NSE:APLLTD

Every FINWIRES story that references NSE:APLLTD, newest first.

Indian Equities Rally on Friday as US-Iran Deal Hopes, Easing Oil Prices Boost Sentiment

Indian benchmark indices rallied on Friday, with the Sensex and Nifty posting their strongest gains in several sessions as optimism surrounding a potential U.S.-Iran agreement and a sharp decline in crude oil prices lifted investor sentiment.The BSE Sensex jumped 1,695.40 points, or 2.3%, to close at 75,527.95, while the NSE Nifty 50 advanced 461.30 points, or 2%, to settle at 23,622.90.Sentiment improved after U.S. President Donald Trump said that negotiations with Iran were nearing completion. Reports indicating that a deal could be finalized in the coming days raised expectations of the reopening of the Strait of Hormuz, easing concerns over global energy supplies. This resulted in a sharp decline in crude oil prices, which further supported risk appetite.On the economic front, the World Bank raised its 2026 growth forecast for India to 6.6% from 6.5%, citing resilient domestic demand, strong rural consumption, and improving urban demand.In corporate developments, Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) received final approval from the U.S. Food and Drug Administration for its generic version of Retin-A Cream, used in the treatment of acne vulgaris.Tata Motors Passenger Vehicles (NSE:TMPV, BOM:500570) is set to increase vehicle prices by up to 1.5% from July as it seeks to offset rising input costs, according to Reuters reports.

^BSENifty 50BOM:500570BOM:533573NSE:APLLTDNSE:TMPV

Asia3d ago

Alembic Pharma Gets Final NoD From USFDA for Tretinoin Cream

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, 0.05%, according to a Friday filing on Indian exchanges.The product is a generic version of Retin-A Cream, 0.05%, of Bausch Health US and is used for the topical treatment of acne vulgaris, the filing said.It has an estimated U.S. market size of $76 million for the 12 months ended March 2026, Alembic said, citing IQVIA data.Shares of the company fell 1% in recent trade.

BOM:533573NSE:APLLTD

Asia4d ago

Alembic Pharmaceuticals Gets USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Larotrectinib Capsules in strengths 25 mg and 100 mg, according to a Thursday filing.The product is a generic version of Vitrakvi Capsules of Bayer Healthcare Pharmaceuticals, the filing said. It is used for the treatment of certain solid tumors with a neurotrophic receptor tyrosine kinase gene fusion, where no satisfactory alternative treatment exists or the disease has progressed after prior therapy, the company said in the filing.Alembic said that after obtaining final approval of this ANDA, it may be "eligible for 180 days of generic marketing exclusivity in the U.S."The company added that the product has an estimated U.S. market size of about $91 million.

BOM:533573NSE:APLLTD

Asia7d ago

Alembic Pharmaceuticals to Acquire 45% Stake in Canadian Venture

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has entered into a shareholders' agreement with Difgen Holdings and Sukhad Juneja to invest in 17989377 Canada Inc., according to a Saturday filing with the Indian bourse.Upon completion of the transaction, Alembic will hold a 45% stake in the Canadian entity, while Difgen Holdings will own 45%. The remaining 10% will be held by other shareholders.The investment will support the establishment of a platform to develop, commercialize, distribute, and market pharmaceutical products in Canada, the company said in the filing.The Canadian company will become an associate of Alembic following completion of the investment, according to the filing.Shares of the company rose 1% in recent trade.

BOM:533573NSE:APLLTD

Asia10d ago

Alembic Pharmaceuticals Gets USFDA Approval for Haloperidol Tablets

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Haloperidol Tablets in strengths of 1 mg, 2 mg, 5 mg, 10 mg and 20 mg, according to a Friday filing on Indian bourses.The product is the generic equivalent of Haldol Tablets marketed by Ortho McNeil Pharmaceutical and is used for the management of psychotic disorders and Tourette's disorder, the company said in the filing.The approved product has an estimated market size of about $27 million for the 12 months ended March 2026, the filing said, citing IQVIA data.With this approval, Alembic has received a cumulative 240 ANDA approvals from the USFDA, comprising 221 final approvals and 19 tentative approvals.

BOM:533573NSE:APLLTD

Asia32d ago

Alembic Pharmaceuticals Gets US FDA's Establishment Inspection Report for Karakhadi, India Unit

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has received an establishment inspection report from the US Food and Drug Administration (US FDA) for its injectable facility (F-III) at Karakhadi in Gujarat, India, according to a Thursday filing to the Indian stock exchanges.The USFDA has inspected the facility between Feb. 9 and Feb. 18.The company's shares were up nearly 2% in recent trade.

BOM:533573NSE:APLLTD

Asia32d ago

Alembic Pharmaceuticals Gets US FDA's Tentative Approval for Darolutamide Tablets

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has received tentative approval from the US Food and Drug Administration (US FDA) for its Darolutamide Tablets, 300 mg, according to a Thursday filing to the Indian stock exchanges.The Darolutamide tablets are therapeutically equivalent to Bayer HealthCare Pharmaceuticals' reference-listed drug Nubeqa Tablets, 300 mg, which are androgen receptor inhibitors used to treat adult patients with prostate cancer.According to IQVIA estimates, Darolutamide Tablets, 300 mg, have an estimated market size of $3.16 billion for the 12 months ended March.The company's shares were up over 1% in recent trade.

BOM:533573NSE:APLLTD

Asia53d ago

Alembic Pharmaceuticals Incorporates Philippines Subsidiary

Alembic Pharmaceuticals (NSE:APLLTD, BOM:506235) has established a subsidiary called Alembic Lifesciences Philippines Inc. in the Philippines, according to a Wednesday filing to the Indian stock exchanges.Shares of the company rose over 2% in Thursday's trading.The company will hold a 99.99% stake in the new entity, which will focus on marketing and distribution of pharmaceutical products in the region, the filing said.

BOM:506235NSE:APLLTD

Asia60d ago

Indian Equities Slip on Thursday Amid Profit Booking in Heavyweights

Indian benchmark indices closed marginally lower on Thursday as profit booking in select large stocks offset early optimism.The BSE Sensex slipped 122.56 points, or 0.2%, to finish at 77,988.68, while the NSE Nifty 50 fell 34.55 points, or 0.1%, to close at 24,196.75.Sentiment remained mildly supported by expectations of a second round of US-Iran talks aimed at easing the ongoing conflict. Uncertainty over timing, however, kept investors cautious.On the macro side, India's Wholesale Price Index (WPI) inflation rose to 3.88% in March, up from 2.13% in February, according to government data released late on Wednesday. Goods and services exports also declined 4.58% year-on-year to $74.11 billion in March.Among stocks, HDFC Asset Management Company (NSE:HDFCAMC, BOM:541729) reported a slight dip in consolidated profit to 6.23 billion rupees in Q4 FY26 from 6.38 billion rupees a year earlier. Revenue from operations rose to 10.5 billion rupees from 9.01 billion rupees, according to its filing.Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) gained after receiving US FDA approval for Methotrexate Injection in both multi-dose and single-dose vials. The drug is used in cancer treatment as well as autoimmune conditions including rheumatoid arthritis and psoriasis.

^BSENifty 50BOM:533573BOM:541729NSE:APLLTDNSE:HDFCAMC

Asia60d ago

Alembic Pharmaceuticals Gets Final Nod from US FDA for Methotrexate Injection

Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) has received final approval from the US Food and Drug Administration (US FDA) for Methotrexate Injection in multi-dose vials and single-dose vials, according to a Thursday filing to the Indian stock exchanges.The methotrexate injection, Hospira's reference listed drug product Methotrexate Injection, is a folate analog metabolic inhibitor indicated for neoplastic diseases.It is also used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis.The company's shares were up nearly 2% in recent trade.

BOM:533573NSE:APLLTD